Pierpaolo Trimboli1, Marco Castellana2, Luca Maria Sconfienza3,4, Camilla Virili5, Lorenzo Carlo Pescatori6, Roberto Cesareo7, Francesco Giorgino2, Roberto Negro8, Luca Giovanella1,9, Giovanni Mauri10. 1. Clinic for Nuclear Medicine and Competence Center for Thyroid Diseases, Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland. 2. Department of Emergency and Organ Transplantation, Section of Internal Medicine, Endocrinology, Andrology and Metabolic Diseases, University of Bari Aldo Moro, Bari, Italy. 3. Department of Biomedical Sciences for Health, Università degli Studi di Milano, Milano, Italy. luca.sconfienza@unimi.it. 4. IRCCS Istituto Ortopedico Galeazzi, Unit of Diagnostic and Interventional Radiology, Milano, Italy. luca.sconfienza@unimi.it. 5. Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy. 6. Postgraduation School in Radiodiagnostic, Università degli Studi di Milano, Milano, Italy. 7. Unit of Metabolic Diseases, S.M.Goretti, Latina Hospital, Latina, Italy. 8. Division of Endocrinology, "V. Fazzi" Hospital, Lecce, Italy. 9. Clinic for Nuclear Medicine, University Hospital and University of Zurich, Zurich, Switzerland. 10. Division of Interventional Radiology, European Institute of Oncology IRCCS, Milan, Italy.
Abstract
BACKGROUND: Image-guided thermal ablations are commonly used in the treatment of thyroid nodules. Radiofrequency ablation (RFA) and laser ablation are the most commonly used. Here we aimed to obtain solid evidence of the long-term efficacy of RFA and laser ablation in benign non-functioning solid thyroid nodules (BNFSTN). METHODS: PubMed, CENTRAL, Scopus, and Web of Science were searched until March 2019. Studies reporting the effectiveness of RFA or laser ablation in patients with BNFSTN in terms of volume reduction rate (VRR), compressive symptoms and cosmetic concerns were included. Complications were also assessed. RESULTS: Out of 963 papers, 12 studies on RFA and 12 on laser ablation were included, assessing 1186 and 2009 BNFSTNs, respectively. Overall, VRR at 6, 12, 24, and 36 months was 60%, 66%, 62%, and 53%. VRR of RFA was 68%, 75%, and 87%, respectively. VRR of laser ablation was 48%, 52%, 45%, and 44%, respectively. Baseline volume of nodules undergone RFA was significantly smaller compared to laser ablation (20.1 ± 22.4 versus 24.6 ± 23.6 ml; p < 0.01). Nodules smaller than 30 ml obtained better outcomes than larger ones. A significant reduction in compressive symptoms and cosmetic concerns was found after RFA. CONCLUSIONS: This meta-analysis showed that both RFA and laser ablation are able to obtain a significant volume reduction in BNFSTNs. A significant volume reduction is already evident at 6 months after thermal ablation and results are stable over the time.
BACKGROUND: Image-guided thermal ablations are commonly used in the treatment of thyroid nodules. Radiofrequency ablation (RFA) and laser ablation are the most commonly used. Here we aimed to obtain solid evidence of the long-term efficacy of RFA and laser ablation in benign non-functioning solid thyroid nodules (BNFSTN). METHODS: PubMed, CENTRAL, Scopus, and Web of Science were searched until March 2019. Studies reporting the effectiveness of RFA or laser ablation in patients with BNFSTN in terms of volume reduction rate (VRR), compressive symptoms and cosmetic concerns were included. Complications were also assessed. RESULTS: Out of 963 papers, 12 studies on RFA and 12 on laser ablation were included, assessing 1186 and 2009 BNFSTNs, respectively. Overall, VRR at 6, 12, 24, and 36 months was 60%, 66%, 62%, and 53%. VRR of RFA was 68%, 75%, and 87%, respectively. VRR of laser ablation was 48%, 52%, 45%, and 44%, respectively. Baseline volume of nodules undergone RFA was significantly smaller compared to laser ablation (20.1 ± 22.4 versus 24.6 ± 23.6 ml; p < 0.01). Nodules smaller than 30 ml obtained better outcomes than larger ones. A significant reduction in compressive symptoms and cosmetic concerns was found after RFA. CONCLUSIONS: This meta-analysis showed that both RFA and laser ablation are able to obtain a significant volume reduction in BNFSTNs. A significant volume reduction is already evident at 6 months after thermal ablation and results are stable over the time.
Authors: W M Tunbridge; D C Evered; R Hall; D Appleton; M Brewis; F Clark; J G Evans; E Young; T Bird; P A Smith Journal: Clin Endocrinol (Oxf) Date: 1977-12 Impact factor: 3.478
Authors: Arian Mansur; Tushar Garg; Apurva Shrigiriwar; Vahid Etezadi; Christos Georgiades; Peiman Habibollahi; Timothy C Huber; Juan C Camacho; Sherif G Nour; Alan Alper Sag; John David Prologo; Nariman Nezami Journal: Diagnostics (Basel) Date: 2022-05-24
Authors: Ralph P Tufano; Pia Pace-Asciak; Jonathon O Russell; Carlos Suárez; Gregory W Randolph; Fernando López; Ashok R Shaha; Antti Mäkitie; Juan P Rodrigo; Luiz Paulo Kowalski; Mark Zafereo; Peter Angelos; Alfio Ferlito Journal: Front Endocrinol (Lausanne) Date: 2021-06-24 Impact factor: 5.555
Authors: H I Al-Mohammed; A Sulieman; Fareed H Mayhoub; Hassan Salah; Celestino Lagarde; M Alkhorayef; Ali Aldhebaib; C Kappas; D A Bradley Journal: Sci Rep Date: 2021-07-15 Impact factor: 4.379
Authors: Whitney Sutton; Joseph K Canner; Lisa M Rooper; Jason D Prescott; Martha A Zeiger; Aarti Mathur Journal: Am J Surg Date: 2020-06-02 Impact factor: 2.565